ReviewCurrent cardiology reports2004
Combination drug treatment of hypertension: have we come full circle?
Review in Current cardiology reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells.Frontiers in genetics · 2019Article
- Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study.Drugs - real world outcomes · 2016Article
- Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.Vascular health and risk management · 2016Review
- Use of combination antihypertensive therapy initiation in older Americans without prevalent cardiovascular disease.Journal of the American Geriatrics Society · 2014Observational
- Should two-drug initial therapy for hypertension be recommended for all patients?Current hypertension reports · 2012Review
- Valsartan combination therapy in the management of hypertension - patient perspectives and clinical utility.Integrated blood pressure control · 2009Article
- Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.Vascular health and risk management · 2009Review
- What factors contribute to the inadequate control of elevated blood pressure?Journal of clinical hypertension (Greenwich, Conn.) · 2008Review
- Optimizing hypertension management in clinical practice.Journal of human hypertension · 2006Review
- Combination pharmacotherapy in hypertension.International urology and nephrology · 2006Review
- Current status of stroke in Qatar: Including data from the BRAINS study.JRSM cardiovascular diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Only 30% of hypertensive patients achieved and maintained adequate blood pressure control on a single drug in recent clinical trials. For the majority of patients who require two or more drugs to lower blood pressure to the currently recommended goals of 140/90 mm Hg or to 130/80 if they are diabetic or have chronic kidney disease, combinations of two or more drugs in a single pill offers an attractive alternative to taking multiple single drugs each day. Research has shown that the simpler the drug regimen the more likely patients are to be compliant in taking medications. Because a reduction in cardiovascular risk is linked to the extent to which elevated blood pressure is reduced, this benefit is not realized by patients who either discontinue their medications or are noncompliant. Carefully selected low doses of two antihypertensive drugs combined in a single pill offers other advantages including greater efficacy compared with high-dose monotherapy, a lower incidence of adverse effects, improved persistence in taking medications, fewer patient visits, and reduced cost to the health care system.
Indexed as
Identifiers
15485601What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.